This dosage is far lower than the dosages of RGZ known to ameliorate both hypertension and endothelial dysfunction.[48] Furthermore, no interference with fetal or placental development has been observed in rodents,[32, 49] and no unexpected PPARγ activation in major maternal organs or adverse effects in dams has been reported. The gene discussed is PPARG; the disease is endothelial dysfunction.